Last reviewed · How we verify
Carfilzomib, proteasome inhibitor; intravenous
Carfilzomib, proteasome inhibitor; intravenous is a Proteasome inhibitor Small molecule drug developed by Pfizer. It is currently in Phase 2 development for Multiple myeloma.
Proteasome inhibitor
Proteasome inhibitor Used for Multiple myeloma.
At a glance
| Generic name | Carfilzomib, proteasome inhibitor; intravenous |
|---|---|
| Sponsor | Pfizer |
| Drug class | Proteasome inhibitor |
| Target | 20S proteasome |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Carfilzomib inhibits the 20S proteasome, a protein complex involved in protein degradation.
Approved indications
- Multiple myeloma
Common side effects
- Anemia
- Thrombocytopenia
- Neutropenia
Key clinical trials
- Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma (PHASE2)
- Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers (PHASE2)
- A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy (PHASE4)
- Combination Therapy With Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung Transplantation (PHASE2)
- A Study of Filanesib (ARRY-520) and Carfilzomib in Patients With Advanced Multiple Myeloma (PHASE2)
- Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies (PHASE1)
- Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Carfilzomib, proteasome inhibitor; intravenous CI brief — competitive landscape report
- Carfilzomib, proteasome inhibitor; intravenous updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about Carfilzomib, proteasome inhibitor; intravenous
What is Carfilzomib, proteasome inhibitor; intravenous?
Carfilzomib, proteasome inhibitor; intravenous is a Proteasome inhibitor drug developed by Pfizer, indicated for Multiple myeloma.
How does Carfilzomib, proteasome inhibitor; intravenous work?
Proteasome inhibitor
What is Carfilzomib, proteasome inhibitor; intravenous used for?
Carfilzomib, proteasome inhibitor; intravenous is indicated for Multiple myeloma.
Who makes Carfilzomib, proteasome inhibitor; intravenous?
Carfilzomib, proteasome inhibitor; intravenous is developed by Pfizer (see full Pfizer pipeline at /company/pfizer).
What drug class is Carfilzomib, proteasome inhibitor; intravenous in?
Carfilzomib, proteasome inhibitor; intravenous belongs to the Proteasome inhibitor class. See all Proteasome inhibitor drugs at /class/proteasome-inhibitor.
What development phase is Carfilzomib, proteasome inhibitor; intravenous in?
Carfilzomib, proteasome inhibitor; intravenous is in Phase 2.
What are the side effects of Carfilzomib, proteasome inhibitor; intravenous?
Common side effects of Carfilzomib, proteasome inhibitor; intravenous include Anemia, Thrombocytopenia, Neutropenia.
What does Carfilzomib, proteasome inhibitor; intravenous target?
Carfilzomib, proteasome inhibitor; intravenous targets 20S proteasome and is a Proteasome inhibitor.
Related
- Drug class: All Proteasome inhibitor drugs
- Target: All drugs targeting 20S proteasome
- Manufacturer: Pfizer — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Multiple myeloma
- Compare: Carfilzomib, proteasome inhibitor; intravenous vs similar drugs
- Pricing: Carfilzomib, proteasome inhibitor; intravenous cost, discount & access